Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.

Mount Sinai researchers have developed a method to uncover the hidden immune cells that harbor the human immunodeficiency virus (HIV), a discovery that brings medical experts one step closer to a cure ...

HIV prevention has advanced with lenacapavir, a yearly injection that blocks the virus's replication, providing long-term ...

A new study led by Western researchers is the first to identify a factor that could influence how fast the pocket where human ...

Every year, my colleagues and I put together a list of what we think are the top 10 breakthrough technologies of that year.

HIV self-testing remains underutilized among not only the general public, but especially people who use drugs.

Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against ...

Nearly half of all new cases in 2022 were in the South. "The frustrating part is we have the tools now to stop it." ...

An annual shot to protect against HIV infection has successfully passed an early safety trial, according to research ...

New real-world and implementation study data highlight the efficacy of ViiV’s long-acting injectables for HIV prevention and ...

Gilead has reported results for a once-yearly intramuscular injection that show blood concentrations of lenacapavir exceeded ...

Phase I trial results show the potential of once-yearly lenacapavir as a long-acting PrEP option for HIV, supporting further ...